alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 32.2**

 

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with theQuarterly Report of AXCESS Inc. (the “***Company***”) on Form 10-QSB for the period endedSeptember 30, 2003, as filed with the Securities and Exchange Commission on thedate hereof (the “***Report***”),I, Allan L. Frank, Vice President, Chief Financial Officer, Secretary andPrincipal Accounting and Financial Officer of the Company, certify, pursuant to18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Actof 2002, that to my knowledge:

 

(1)           The Report fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,as applicable; and

 

(2)           The information contained in theReport fairly presents, in all material respects, the financial condition andresults of operations of the Company at the dates and for the periodsindicated.

 

 
| /S/ ALLAN L.  FRANK                                                                                 |   |
|-----------------------------------------------------------------------------------------------------|--------|
| Allan L.  Frank                                                                                     |
| Vice  President, Chief Financial Officer, Secretary and Principal Accounting and  Financial Officer |
|                                                                                                |
| Dated:  November 13, 2003                                                                      |

 

----
Mary Rose GREENE, et al., petitioners, v. DISTRICT OF COLUMBIA.

No. 12-1265.

Supreme Court of the United States

May 20, 2013.

Petition for writ of certiorari to the District of Columbia Court of Appeals denied.
<TABLE> <S> <C>


<ARTICLE> 5

<LEGEND>
The schedule contains summary financial information extracted from Winthrop
Residential Associates III, A Limited Partnership and is qualified in its
entirety by reference to such financial statements.
</LEGEND>

<MULTIPLIER>      1

       
<S>                                                     <C>
<PERIOD-TYPE>                                                 9-MOS
<FISCAL-YEAR-END>                                       DEC-31-1997
<PERIOD-START>                                          JAN-01-1997
<PERIOD-END>                                            SEP-30-1997
<CASH>                                                    1,248,000
<SECURITIES>                                                      0
<RECEIVABLES>                                                     0
<ALLOWANCES>                                                      0
<INVENTORY>                                                       0
<CURRENT-ASSETS>                                                  0
<PP&E>                                                    4,974,000
<DEPRECIATION>                                            2,661,000
<TOTAL-ASSETS>                                            4,127,000
<CURRENT-LIABILITIES>                                             0
<BONDS>                                                   2,599,000
<COMMON>                                                          0
<PREFERRED-MANDATORY>                                             0
<PREFERRED>                                                       0
<OTHER-SE>                                                1,219,000
<TOTAL-LIABILITY-AND-EQUITY>                              4,127,000
<SALES>                                                           0
<TOTAL-REVENUES>                                          1,166,000
<CGS>                                                             0
<TOTAL-COSTS>                                               650,000
<OTHER-EXPENSES>                                                  0
<LOSS-PROVISION>                                                  0
<INTEREST-EXPENSE>                                          160,000
<INCOME-PRETAX>                                             344,000
<INCOME-TAX>                                                      0
<INCOME-CONTINUING>                                         344,000
<DISCONTINUED>                                                    0
<EXTRAORDINARY>                                                   0
<CHANGES>                                                         0
<NET-INCOME>                                                344,000
<EPS-PRIMARY>                                                 12.72
<EPS-DILUTED>                                                 12.72
        


</TABLE>
Office of Global Policy and Strategy 

OGPS STATEMENT

May 31, 2023

 FDA Expands Mutual Recognition Agreement with European Union

Today, the U.S. Food and Drug Administration (FDA) and the European Union (EU) are 

announcing their decision to expand the scope of the U.S.-EU Mutual Recognition 

Agreement (MRA) Sectoral Annex for Pharmaceutical Good Manufacturing Practices 

(GMP) to include inspections of veterinary pharmaceuticals (also called “animal drugs”). 

This MRA entered into force on November 1, 2017, but initially included only 

pharmaceuticals intended for human use. Today’s action to include animal drugs in the 

MRA is an important step in ensuring the safety and quality of animal drug products and 

will enhance efficiencies for the U.S. and EU regulatory systems.

For FDA, an MRA is an agreement between two or more countries to recognize an 

inspection by the other country, and this is the first step toward strengthening use of 

each other’s animal drug inspection expertise and resources. The overall goal of the 

MRA is to produce greater efficiencies for both regulatory systems and provide a more 

practical means for both the FDA and the EU to oversee the facilities that manufacture 

animal drugs. 

By utilizing each other’s inspection reports and related information, an MRA can 

ultimately enable the FDA and the EU to avoid duplication of some animal drug 

inspections and enable regulators to devote more resources to other parts of the world 

where there may be greater risk. 

Over the past several months, the FDA has taken numerous steps to prepare for 

expanding and implementing the MRA’s coverage to include animal drugs. Among other 

things, this has included sharing information with the EU about FDA’s Center for 

Veterinary Medicine’s oversight of animal drug manufacturing in the United States; 

observing EU audits of individual member states including observations of inspections 

conducted by EU member state inspectors; and conducting assessments of some EU 

member states’ regulatory frameworks, which found that these member states have the 

capability, capacity, and procedures to carry out routine GMP surveillance inspections 

that meet FDA requirements for animal drugs.
FDA currently has confirmed that 16 European Union Member States have the 

capability of carrying out GMP inspections for certain veterinary products at a level 

equivalent to the United States. The 16 Member States include: Austria, Belgium, 

Bulgaria, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Luxembourg, 

Netherlands, Poland, Portugal, Slovenia, and Spain.

With this expanded MRA, FDA can rely on GMP inspections of veterinary product 

facilities of these 16 Member States and the European Union will rely on inspections 

conducted by the FDA.

###

Additional Resources:

Mutual Recognition Agreement

Mutual Recognition Agreement / Frequently Asked Questions and Answers
Billy D. McKISSIC, petitioner, v. UNITED STATES.

No. 12-9077.

Supreme Court of the United States

April 1, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
Difankh ASAR, aka James Walter Gist, petitioner, v. UNITED STATES.

No. 12-10373.

Supreme Court of the United States

June 24, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
Exhibit 32.1  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  In connection with the Quarterly Report of Thunder Mountain Gold Inc, (the "Company") on Form 10-QSB for the period ended June 30, 2007, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, E. James Collord, President, Director and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  /s/ E. James Collord By __________________________________ E.  James Collord President, Director and Chief Executive Officer Date:   August 14, 2007
In re Marek A. KWASNIK, petitioner.

No. 12-1214.

Supreme Court of the United States

May 13, 2013.

Petition for writ of habeas corpus denied.
Sherry-Jolene GABBARD, petitioner, v. TENNESSEE ELECTIONS COMMISSION, et al.

No. 12-8850.

Supreme Court of the United States

April 22, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
Linwood Clifton WOOD, petitioner, v. UNITED STATES.

No. 12-10143.

Supreme Court of the United States

June 3, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
Miguel Angel RAMIREZ, Appellant, v. HERITAGE PROPERTY & CASUALTY INSURANCE COMPANY, Appellee.

No. 3D18-1107

District Court of Appeal of Florida, Third District.

Opinion filed May 29, 2019

Giasi Law, P.A., and Melissa A. Giasi (Tampa), for appellant.

Alisha N. Wilson and Pedro M. Ortiz (Sunrise); Link & Rockenbach, PA, and Kara Berard Rockenbach and Daniel M. Schwarz (West Palm Beach), for appellee.

Before LOGUE, SCALES, and HENDON, JJ.

PER CURIAM.

Affirmed. *See**Gonzalez v. Citizens Prop. Ins. Corp.*, No. 3D17-2609, 273 So.3d 1031, ----, 2019 WL 1141236, at *3 (Fla. 3d DCA Mar. 13, 2019) ("In short, the affidavits opposing summary judgment must identify admissible evidence that creates a genuine issue of material fact.") (citations and quotations omitted).
Maria CALDERON, petitioner, v. EVERGREEN OWNERS, INC., et al.

No. 12-8470.

Supreme Court of the United States

April 1, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.
EXHIBIT A

USDC IN/ND case 2:12-cv-00523-TLS document 74-1 filed 05/29/15 page 1 of 2
EXHIBIT A

Case 3:17-cv-00939-WHA Document 203-1 Filed 04/10/17 Page 1 of 2
Case 3:17-cv-00939-WHA Document 203-1 Filed 04/10/17 Page 2 of 2
LEASE
CONTRACT

     

    Lessor
(hereinafter
referred to as Party A):Fengling
Wang

     

    Lessee
(hereinafter
referred to as Party B):Shanghai Baby-Fox
Fashion Co., Ltd.

     

    Party A
and B have reached an agreement through friendly consultation to conclude the
following contract.

     

    Party A
will lease to Party B the premises and attached facilities owned by itself for
free which is located at Room 1501, No.98, 158th Lane, Baocheng Rd., Xinzhuang
Town, Minhang District, Shanghai, China.

     

    1. Lease
term

     

    The lease
term will be from January 1st, 2008 to December 31, 2012.

     

    2. Rent
of RMB 60,000 is paid annually with RMB 5,000 each month.

     

    3.
Obligations of Party A and Party B

     

    1) Party A will
guarantee the lease right of the premises. Otherwise, Party A will be
responsible to compensate party B‘s losses.

     

    2) Party A will
provide the premises and attached facilities on schedule to Party B for using.
And Party A shall not interrupt Party B’s business without Party B’s
permission.

     

    3) Party B should
take good care of the premises. Otherwise, Party B will be responsible for the
damages caused by it.

     

    4) Party B will bear
the cost of utilities such as taxes, telephone communications, water,
electricity, cleaners, property management, securities and temporary residence
permit on time during the lease term.

     

    4.
Contract is effective with signatures and stamps of both Party A and Party B.
Previous contracts are expired to use.

     

    
      
        	
                Party
      A’s Signature:

              	
                Party
      B’s Signature:

              
	 	 
	
                Fengling
      Wang

              	
                Shanghai
      Baby-Fox Fashion Co., Ltd.

              


      

    

     

      Date :
Januray 1st,
2008
Exhibit
32.1





CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002





In
connection with the Annual Report of Witel Corp. (the “Company”) on Form 10-K
for the period ended December 31, 2008 as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Gary Tsitron, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted
pursuant to section 906 of the Sarbanes-Oxley Act of 2002, That to the best of
my knowledge:





(1)           The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2)           The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.





Witel
Corp.




By /s/ Gary
Tsitron


Gary
Tsitron


Chairman,
CEO


April 3,
2009
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

WAYMO LLC,

Plaintiff,

 v.

UBER TECHNOLOGIES, INC., et al.,

Defendants. /

No. C 17-00939 WHA

ORDER RE SPECIAL

MASTER’S ACCESS TO

SEALED MATERIAL

Going forward, the special master shall be automatically included on the Court’s service

list for material filed under seal.

IT IS SO ORDERED.

Dated: May 15, 2017. WILLIAM ALSUP

UNITED STATES DISTRICT JUDGE

Case 3:17-cv-00939-WHA Document 436 Filed 05/15/17 Page 1 of 1
Mary Ann SABER, et al., petitioners, v. Sam SABER, et al.; and Mary Ann Saber, et al., petitioners, v. Sam Saber, et al.

No. 12-8852.

Supreme Court of the United States

June 17, 2013.

Petition for rehearing denied.

Justice ALITO took no part in the consideration or decision of this petition.
<PAGE>
                                                                    Exhibit 32.2

                          TEXTRON FINANCIAL CORPORATION
                            CERTIFICATION PURSUANT TO
                               RULE 13A-14(B) AND
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

   In connection with the Quarterly Report of Textron Financial Corporation (the
"Company") on Form 10-Q for the period ended March 31, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Thomas
J. Cullen, Executive Vice President and Chief Financial Officer of the Company,
certify, pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

    1.  the Report fully complies with the requirements of Section 13(a) or
        15(d) of the Securities Exchange Act of 1934; and

    2.  the information contained in the Report fairly presents, in all material
        respects, the financial condition and results of operations of the
        Company.


                                    Textron Financial Corporation

                                    /s/ Thomas J. Cullen
                                    ------------------------------------------
                                    Thomas J. Cullen
                                    Executive Vice President and
                                    Chief Financial Officer


Date: May 10, 2004
SCWC

- 17

- 0000143

IN THE SUPREME COURT OF THE STATE OF HAWAI  I

STATE OF HAWAI  I , Respondent/Plaintiff

- Appellee,

vs.

LARINA M.K. BENITEZ , Petitioner/Defendant

- Appellant.

CERTIORARI TO THE INTERMEDIATE COURT OF APPEALS (CAA P

- 17

- 0000143; CASE NO. 1DTC

- 16

- 070804)

ORDER OF CORRECTION (By: Pollack, J.)

IT IS HEREBY ORDERED that the Order Rejecting Application for Writ of Certiorari filed December 14 , 2018 , is
corrected as follows :

In the caption, “ CR. NO. 1DCT

- 16

- 070804 ” is changed to

“ CASE NO. 1DTC

- 16

- 070804 ”

.

The Clerk of the Court is directed to take all necessary steps to notify the publishing agencies of th is change. DATED: Honolulu, Hawai  i , December 19 , 201 8

. /s/ Richard W. Pollack
Associate Justice Electronically Filed Supreme Court SCWC-17-0000143 19-DEC-2018 03:21 PM
EXHIBIT 32.1



CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002



I, E. James Collard, President and  Director and Chief Executive Officer of Thunder Mountain Gold, Inc. (the Registrant) do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:



1.

This Quarterly Report on Form 10-QSB of the Registrant for the fiscal period ended September 30, 2003, as filed with the Securities and Exchange Commission (the report), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



2.

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date:  October 24, 2003

/s/ E. James Collord

E. James Collord, President and Director

Chief Executive  Officer
Ramon Emanuel SMITH, petitioner, v. UNITED STATES.

No. 12-9750.

Supreme Court of the United States

May 13, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
<PAGE>

                                                                    EXHIBIT 31.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER

            PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lawrence Butler, certify that:

1. I have reviewed this report on Form 10-Q of Alpha Technologies Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

b) (Intentionally left Blank)

c) Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.

/s/ Lawrence Butler
---------------------
Lawrence Butler
Chief Executive Officer
June 14, 2004

                                       23
CENTER FOR TOBACCO PRODUCTS 

Amendment Tips

Completing Form FDA 4057a

Form FDA 4057a—Premarket Tobacco Product Application Amendment and General Correspondence 

Submission is a required form for applicants to use when submitting amendments and other general 

correspondence to FDA. In most circumstances, the agency can only consider premarket tobacco 

product application (PMTA) amendments for review that include Form FDA 4057a, which can be 

downloaded at http://bit.ly/3lxJWcb (PDF 926 KB).

In general, when submitting amendments for a PMTA, FDA will review the required Form FDA 4057a 

first. If required content is missing from the form, FDA may not continue reviewing the amendment. 

This fact sheet offers tips for correctly completing Form FDA 4057a.

Section I—Applicant Identification 

• Fill out Subsection A so that the information matches the application you are amending.

• If you are adding, updating, replacing, or removing an applicant, authorized representative,

point of contact, U.S. agent, or manufacturer, carefully read and follow the instructions under

Subsection C. These instructions explain what demographic information is needed based on

the change(s) being made.

Section III—Submission Information

• Select “Amendment” under the “Type of Submission.”

• Include the FDA submission tracking number (STN) assigned to the application you are

amending.

• Select the appropriate amendment response type (i.e., “Deficiency Letter,” “Unsolicited,” or

“Other”). If selecting “Unsolicited” or “Other,” include a description under the “Submission

Summary.”

Section VI—Certification Statement

• Complete the “Certification Statement,” as required by 21 CFR 1114.9(a) and described in

21 CFR 1114.7(m).

• The “Certification Statement” is required and separate from any signature used on the electronic

forms for eSubmitter and the CTP Portal. You can learn more about submitting documents via the

CTP Portal at http://bit.ly/3JzeHHA.
CENTER FOR TOBACCO PRODUCTS 

Amendment Tips

Completing Form FDA 4057a

If you have questions or need additional support, please call the CTP Call Center at 1-877-287-1373

between 9 a.m. and 4 p.m. ET. 

Learn more about preparing PMTAs and amendments at http://bit.ly/3YalmMu.

Finding Your STN

You can find your STN in the CTP Portal at

ctpportal.fda.gov. Watch this video to help

you use the CTP Portal and locate your 

STN: http://bit.ly/43nG4w4.

If you do not have a CTP Portal account and you 

submitted a physical copy of your amendment, 

you can get your STN by contacting your 

assigned Regulatory Health Project Manager 

(RHPM) or FDA.

If you are unsure of your assigned RHPM, FDA can help. 

Contact FDA by calling 1-877-287-1373 or emailing AskCTP@fda.hhs.gov.

CONTACT US

1.877.CTP.1373 | AskCTP@FDA.hhs.gov | www.fda.gov/tobacco

FDA Center for Tobacco Products | 10903 New Hampshire Avenue | Silver Spring, MD 20993-0002 CTP-239 | Last Updated April 2023